Xilio Therapeutics Inc (XLO)
1.14
+0.06
(+5.56%)
USD |
NASDAQ |
May 17, 16:00
1.14
0.00 (0.00%)
After-Hours: 17:18
Xilio Therapeutics Research and Development Expense (Quarterly): 10.40M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.40M |
| December 31, 2023 | 11.74M |
| September 30, 2023 | 11.05M |
| June 30, 2023 | 13.22M |
| March 31, 2023 | 16.13M |
| December 31, 2022 | 15.00M |
| September 30, 2022 | 13.04M |
| June 30, 2022 | 16.25M |
| Date | Value |
|---|---|
| March 31, 2022 | 14.92M |
| December 31, 2021 | 11.35M |
| September 30, 2021 | 10.47M |
| June 30, 2021 | 17.74M |
| March 31, 2021 | 11.62M |
| December 31, 2020 | 17.67M |
| September 30, 2020 | 11.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.40M
Minimum
Mar 2024
17.74M
Maximum
Jun 2021
13.47M
Average
13.04M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences Inc | 3.95B |
| FibroGen Inc | 38.39M |
| Avalo Therapeutics Inc | 1.867M |
| IGM Biosciences Inc | 43.82M |
| AEON Biopharma Inc | -- |